Antiopioid peptides

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 1543-1549

  Han, Ji Sheng ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884934224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00210-4     Document Type: Chapter

References (34)

1. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006, 26:12014-12022.
2. Bocheva A., Dzambazova-Maximova E. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol 2004, 26:673-677.
3. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., Iversen S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990, 176:35-44.
4. Erchegyi J., Kastin A.J., Zadina J.E. Isolation of a novel tetrapeptide with opiate and antiopiate activity from human brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1). Peptides 1992, 13:623-631.
5. Fang Q., Jiang T.N., Li N., Han Z.L., Wang R. Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice. Protein Pept Lett 2011, 18:403-409.
6. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219:310-312.
7. Gospic K., Gunnarsson T., Fransson P., Ingvar M., Lindefors N., Petrovic P. Emotional perception modulated by an opioid and a cholecystokinin agonist. Psychopharmacology (Berl) 2008, 197:295-307.
8. Han J.S. Cholecystokinin octapeptide (CCK-8): a negative feedback control mechanism for opioid analgesia. Prog Brain Res 1995, 105:263-271.
9. Han J.S., Terenius L. Neurochemical basis of acupuncture analgesia. Ann Rev Pharmacol Toxicol 1982, 22:193-220.
10. Han N.L., Luo F., Bian Z.P., Han J.S. Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats. Pain 2000, 85:465-469.
11. Hebb A.L., Poulin J.F., Roach S.P., Roach S.P., Zacharko R.M., Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiat 2005, 29:1225-1238.
12. Heinricher M.M., McGaraughty S., Tortorici V. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001, 85:280-286.
13. Hu E., Calò G., Guerrini R., Ko M.C. Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 2010, 148:107-113.
14. Kastin A.J., Olson R.D., Ehrensing R.H., Berzas M.C., Schally A.V., Coy D.H. MIF-1's differential actions as an opiate antagonist. Pharmacol Biochem Behav 1979, 11:721-723.
15. Kersanté F., Wang J.Y., Chen J.C., Mollereau C., Zajac J.M. Anti-opioid effects of neuropeptide FF receptors in the ventral tegmental area. Neurosci Lett 2011, 488:305-309.
16. Liu N.J., Xu T., Xu C., Li C.Q., Yu Y.X., Kang H.G., et al. Cholecystokinin octapeptide reverses mu-opioid-receptor-mediated inhibition of calcium current in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1995, 275:1293-1299.
17. Miranda-Paiva C.M., Canteras N.S., Sukikara M.H., Nasello A.G., Mackowiak I.I., Felicio L.F. Periaqueductal gray cholecystokinin infusions block morphine-induced disruption of maternal behavior. Peptides 2007, 28:657-662.
18. Mogil J.S., Grisel J.E., Zhangs G., Belknap J.K., Grandy D.K. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 1996, 214:131-134.
19. Mollereau C., Roumy M., Zajac J.M. Opioid-modulating peptides: mechanisms of action. Curr Top Med Chem 2005, 5:341-355.
20. Rady J.J., Fujimoto J.M. Nociceptin and dynorphin A(1-17) produce antianalgesia through independent systems in mice. Life Sci 2002, 70:1085-1093.
21. Sandrini M., Vitale G., Pini L.A., Lopetuso G., Romualdi P., Candeletti S. Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. Eur J Pharmacol 2005, 507:43-48.
22. Takenaka Y., Shimano T., Yamada Y., Yoshida M., Ohinata K., Yoshikawa M. Enterostatin (APGPR) suppresses the analgesic activity of morphine by a CCK-dependent mechanism. Peptides 2008, 29(4):559-563.
23. Tang N.M., Dong H.W., Wang X.M., Tsui Z.C., Han J.S. Cholecystokinin antisense RNA increases the analgesic effect induced by electroacupuncture or low dose morphine: conversion of low responder rats into high responders. Pain 1997, 71:71-80.
24. Tian J.H., Xu W., Fang Y., Mogil J.S., Grisel J.E., Grandy D.K., et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 1997, 120:676-680.
25. Torres-López J.E., Juárez-Rojop I.E., Granados-Soto V., Diaz-Zagoya J.C., Flores-Murrieta F.J., Ortíz-López J.U., et al. Peripheral participation of cholecystokinin in the morphine-induced peripheral antinociceptive effect in non-diabetic and diabetic rats. Neuropharmacology 2007, 52:788-795.
26. Tortorici V., Nogueira L., Salas R., Vanegas H. Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 2003, 102:9-16.
27. Veraksits A., Runkorg K., Kurrikoff K., Raud S., Abramov U., Matsui T., et al. Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology 2003, 166:168-175.
28. Wang J.Q., Fibuch E.E., Sakurada S., Han J.S. Anti-opioid peptides. In: Biologically active peptides. Elsevier 2006, 1345-1350. [Chapter 187].
29. Watanabe H., Nakayama D., Ito K., Watanabe C., Mizoguchi H., Fujimura T., et al. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective μ2-opioid receptor antagonist in the mouse. J Pharmacol Exp Ther 2005, 312:1075-1081.
30. Yamada Y., Ohinata K., Lipkowski A.W., Yoshikawa M. Rapakinin, Arg-Ile-Tyr, derived from rapeseed napin, shows anti-opioid activity via the prostaglandin IP receptor followed by the cholecystokinin CCK(2) receptor in mice. Peptides 2011, 32:281-285.
31. Zaveri N.T. The Nociceptin/Orphanin FQ Receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem 2011, 11:1151-1156.
32. Zhang M., Wang X.M., Zhang D.B., Xu G.H., Dong H.W., Yu Y.X., et al. Orphanin FQ antagonizes the inhibition of Ca2 currents induced by μ-opioid receptors. J Mol Neurosci 2005, 25:21-28.
33. Zhang X., Lucas G.A., Elde R., Wiesenfeld-Hallin Z., Hokfelt T. Effect of morphine on cholecystokinin and μ-opioid receptor-like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation. Neuroscience 2000, 95:197-207.
34. Zhang W., Gardell S., Zhang D., Xie J.Y., Agnes R.S., Badghisi H., et al. Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain 2009, 132(Pt 3):778-787.